3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NIH
4
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
6
Breast
5
Gastrointestinal
4
Head & Neck
3
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Docetaxel
229
Radiotherapy
206
Magnetic Resonance Spectroscopy
204
Radiosurgery
176
Gemcitabine
155
pembrolizumab
150
Nivolumab
147
enzalutamide
140
Prednisone
129
Cisplatin
123
Leuprolide
119
Androgen Antagonists
117
Abiraterone Acetate
114
Sunitinib
106
Specimen Handling
94
Surveys and Questionnaires
91
Goserelin
91
bicalutamide
90
Carboplatin
88
Ipilimumab
82
gallium 68 PSMA-11
80
Blood Specimen Collection
78
Everolimus
73
apalutamide
72
Radiation
71
Standard of Care
68
Biopsy
68
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
66
Paclitaxel
64
Cyclophosphamide
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
bintrafusp alfa protein, human
×
Genitourinary
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled